Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Transmedics Group Inc (NASDAQ: TMDX) closed at $123.94 in the last session, down -2.50% from day before closing price of $127.12. In other words, the price has decreased by -$2.50 from its previous closing price. On the day, 1.07 million shares were traded.
Ratios:
We take a closer look at TMDX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.32 and its Current Ratio is at 9.10. In the meantime, Its Debt-to-Equity ratio is 1.95 whereas as Long-Term Debt/Eq ratio is at 1.94.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 27 ’25 when Basile Edward M sold 5,000 shares for $126.45 per share. The transaction valued at 632,250 led to the insider holds 2,866 shares of the business.
EDWARD BASILE bought 5,000 shares of TMDX for $632,250 on May 27 ’25. On May 23 ’25, another insider, Weill David, who serves as the Director of the company, sold 732 shares for $123.88 each. As a result, the insider received 90,680 and left with 12,134 shares of the company.
Valuation Measures:
As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 91.09, and their Forward P/E ratio for the next fiscal year is 49.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.01. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.59 while its Price-to-Book (P/B) ratio in mrq is 15.74.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 30.65%, while the 200-Day Moving Average is calculated to be 26.60%.
Shares Statistics:
A total of 33.83M shares are outstanding, with a floating share count of 32.59M. Insiders hold about 3.69% of the company’s shares, while institutions hold 117.62% stake in the company.
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of Transmedics Group Inc (TMDX) in the stock market.The consensus estimate for the next quarter is $0.3, with high estimates of $0.36 and low estimates of $0.26.
Analysts are recommending an EPS of between $1.93 and $1.7 for the fiscal current year, implying an average EPS of $1.79. EPS for the following year is $2.48, with 6.0 analysts recommending between $2.75 and $2.12.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $146.64M. It ranges from a high estimate of $150.01M to a low estimate of $144M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $114.31MFor the next quarter, 8 analysts are estimating revenue of $140.82M. There is a high estimate of $145.3M for the next quarter, whereas the lowest estimate is $138.09M.
A total of 10 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $585.4M, while the lowest revenue estimate was $576.27M, resulting in an average revenue estimate of $579.82M. In the same quarter a year ago, actual revenue was $441.54MBased on 9 analysts’ estimates, the company’s revenue will be $692.39M in the next fiscal year. The high estimate is $721.6M and the low estimate is $651.75M.
